Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest quarterly earnings
Latest investor presentation
Latest clinical presentation
Latest publications
Annual report
NASDAQ:NVAX
Loading data...
Reports & financials by fiscal year
Fiscal yearQuarterly earningsAnnual reports & proxy statementsQuarterly filings
2024
Quarterly earnings
Earnings presentation:
Press Release:
Annual reports & proxy statements
Quarterly filings
2023
Quarterly earnings
Earnings presentation:
Press Release:
Annual reports & proxy statements
Quarterly filings
2022
Quarterly earnings
Earnings presentation:
Press Release:
Annual reports & proxy statements
Quarterly filings
2021
Quarterly earnings
Earnings presentation:
Press Release:
Annual reports & proxy statements
Quarterly filings
2020
Quarterly earnings
Press Release:
Annual reports & proxy statements
Quarterly filings
2019
Quarterly earnings
Press Release:
Annual reports & proxy statements
Quarterly filings
2018
Quarterly earnings
Press Release:
Annual reports & proxy statements
Quarterly filings
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Lisa Dunkle

Over my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges and I firmly believe in the platform that we use to manufacture our recombinant protein. Our technology is key as we continue to respond to challenges posed by the SARS-CoV-2 endemic and other vaccine-preventable infectious diseases. 

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.

Graph icon